Natural killer cell therapy - Shanghai iCELL Biotechnology/The Second Affiliated Hospital of Fujian Medical University
Latest Information Update: 26 Nov 2016
At a glance
- Originator Shanghai iCELL Biotechnology
- Class Cell therapies
- Mechanism of Action Natural killer cell stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Spinal cord disorders
Most Recent Events
- 01 Jul 2016 Phase-I clinical trials in Spinal cord disorders (In adults, In the elderly) in China (IV) (NCT02961712)